Skip to main content

ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study

Completed · NCT06526546

Conditions: Paroxysmal Atrial Fibrillation

At a glance

Research payments reported, 2025
$990,823
U.S. investigators named
25
Sites paid
26
Planned or actual enrollment
364

About the trial

Sponsor
Boston Scientific Corporation
Dates
Started 2024-10-31; completion 2025-12-08
Results posted
Not yet

The (ADVENT LTO) is an observational, non-significant risk study to assess the progression of atrial fibrillation in subjects who received ablation treatment with either the FARAPULSE Pulsed Field Ablation System or thermal ablation in the ADVENT Trial.

From ClinicalTrials.gov, last updated 2026-03-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $990,823 in research payments for this study in 2025 (73 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.